{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:00:27Z","timestamp":1770984027519,"version":"3.50.1"},"reference-count":0,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2001,12,25]],"date-time":"2001-12-25T00:00:00Z","timestamp":1009238400000},"content-version":"vor","delay-in-days":419,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2000,11]]},"abstract":"<jats:p>Abstract: This phase IIa, randomised, single\u2010blind, placebo\u2010controlled study was conducted to determine the dose of recombinant human granulocyte colony\u2010stimulating factor (lenograstim) suitable for use in AIDS patients. The study was conducted at 27 European AIDS\/HIV centres, and recruited 69 AIDS patients with an initial episode or relapse of cytomegalovirus infection (neurological site excluded) and an absolute neutrophil count (ANC) 1.0\u00d710<jats:sup>9<\/jats:sup>\/L upon diagnosis or between days 1 and 12 of ganciclovir (GCV) treatment. The patients were randomised to placebo (<jats:italic>n<\/jats:italic>=14) or one of four lenograstim arms: 150\u2003\u00b5g\/m<jats:sup>2<\/jats:sup>\/d (the standard onco\u2010haematology dose, <jats:italic>n<\/jats:italic>=13) or 100 (<jats:italic>n<\/jats:italic>=13), 50 (<jats:italic>n<\/jats:italic>=15), or 25\u2003\u00b5g\/m<jats:sup>2<\/jats:sup>\/d (<jats:italic>n<\/jats:italic>=14). In all groups, the planned dose of GCV was 10mg\/kg\/d for 21\u2003d. Median ANC at weeks 2 and 3 was significantly higher in each lenograstim group than in the placebo group (<jats:italic>p<\/jats:italic>=0.05). At week 3, median ANC (\u00d710<jats:sup>9<\/jats:sup>\/L) was 0.7 in the placebo group, compared with 6.0, 7.4, 4.5, and 2.0 in the 150, 100, 50, and 25\u2003\u00b5g<jats:sup>2<\/jats:sup>\/d lenograstim groups, respectively. Median ANC was not significantly different between the 150, 100, and 50\u2003\u00b5g\/m<jats:sup>2<\/jats:sup>\/d lenograstim groups at any time point, but significantly higher in the 50 than in the 25\u2003\u00b5g\/m<jats:sup>2<\/jats:sup>\/d group at weeks 2 (<jats:italic>p<\/jats:italic>=0.05) and 3 (<jats:italic>p<\/jats:italic>=0.02). Lenograstim was generally well tolerated, leading to no severe adverse events. In conclusion, lenograstim 50\u00b5g\/m<jats:sup>2<\/jats:sup>\/d is suitable for the treatment of ganciclovir\u2010induced neutropenia and is safe. These results should help the physician choose an optimal and cost\u2010efficient regimen for patients with AIDS\u2010related neutropenia when rHuG\u2010CSF support is indicated.<\/jats:p>","DOI":"10.1034\/j.1600-0609.2000.065005337.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T13:49:50Z","timestamp":1047390590000},"page":"337-343","source":"Crossref","is-referenced-by-count":18,"title":["Lenograstim for the treatment of neutropenia in patients receiving ganciclovir for cytomegalovirus infection: a randomised, placebo\u2010controlled trial in AIDS patients"],"prefix":"10.1111","volume":"65","author":[{"given":"M\u2010L.","family":"Dubreuil\u2010Lemaire","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Vittecoq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Panelatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Tharaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Palisses","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Gharakhanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Rozenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"GCS 309 European Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,25]]},"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.065005337.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1600-0609.2000.065005337.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1600-0609.2000.065005337.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,29]],"date-time":"2023-10-29T03:56:51Z","timestamp":1698551811000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1600-0609.2000.065005337.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,11]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,11]]}},"alternative-id":["10.1034\/j.1600-0609.2000.065005337.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1600-0609.2000.065005337.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,11]]}}}